Business Description
Zai Lab Ltd
ISIN : US98887Q1040
Share Class Description:
MEX:ZLAB N: ADR Repr 1 ShsTotal Employee Number:
1,797Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.85 | |||||
Equity-to-Asset | 0.6 | |||||
Debt-to-Equity | 0.35 | |||||
Debt-to-EBITDA | -1.46 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.06 | |||||
Beneish M-Score | -3.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 23.2 | |||||
3-Year EBITDA Growth Rate | 31.7 | |||||
3-Year EPS without NRI Growth Rate | 23.8 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
3-Year Book Growth Rate | -15.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.84 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.4 | |||||
Quick Ratio | 2.19 | |||||
Cash Ratio | 1.68 | |||||
Days Inventory | 131.1 | |||||
Days Sales Outstanding | 66.13 | |||||
Days Payable | 221.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.8 | |||||
Shareholder Yield % | -3.61 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.91 | |||||
Operating Margin % | -52.19 | |||||
Net Margin % | -39.3 | |||||
EBITDA Margin % | -34.96 | |||||
FCF Margin % | -29.33 | |||||
OCF Margin % | -22.42 | |||||
ROE % | -23.81 | |||||
ROA % | -15.45 | |||||
ROIC % | -68.4 | |||||
3-Year ROIIC % | 65.49 | |||||
ROC (Joel Greenblatt) % | -90.19 | |||||
ROCE % | -22.05 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 160.08 | |||||
PS Ratio | 4.65 | |||||
PB Ratio | 3.21 | |||||
Price-to-Tangible-Book | 3.64 | |||||
EV-to-EBIT | -9.94 | |||||
EV-to-EBITDA | -10.91 | |||||
EV-to-Revenue | 3.82 | |||||
EV-to-Forward-Revenue | 3.36 | |||||
EV-to-FCF | -13.02 | |||||
Price-to-GF-Value | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.16 | |||||
| Price-to-Net-Cash | 9.33 | |||||
Earnings Yield (Greenblatt) % | -10.06 | |||||
FCF Yield % | -6.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zai Lab Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 8,312.971 | ||
| EPS (TTM) (MXN) | -31.072 | ||
| Beta | -0.9854 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (MXN) | - | ||
| 20-Day SMA (MXN) | 810 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (MXN) | 810 - 810 | ||
| Shares Outstanding (Mil) | 112.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zai Lab Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zai Lab Ltd Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 127 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 126 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:00 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 35 days | ||
| General meeting for 2026 | 2026-06-17 08:00 | 810.00 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 810.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 810.00 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-20 08:30 | 810.00 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:00 | 810.00 (+0.00%) | ||
| Annual report for 2025 | 2026-02-26 | 810.00 (+0.00%) |
Show
Entries
Zai Lab Ltd Frequently Asked Questions
What is Zai Lab Ltd(MEX:ZLAB N)'s stock price today?
The current price of MEX:ZLAB N is MXN810.00. The 52 week high of MEX:ZLAB N is MXN810.00 and 52 week low is MXN810.00.
When is next earnings date of Zai Lab Ltd(MEX:ZLAB N)?
The next earnings date of Zai Lab Ltd(MEX:ZLAB N) is 2026-08-07 Est..
Does Zai Lab Ltd(MEX:ZLAB N) pay dividends? If so, how much?
Zai Lab Ltd(MEX:ZLAB N) does not pay dividend.
Press Release
Articles on Zai Lab Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers